251 results on '"Denys, Hannelore"'
Search Results
2. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
3. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup
4. Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer
5. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
6. Exclusion of non-Involved uterus from the target volume (EXIT-trial): An individualized treatment for locally advanced cervical cancer using modern radiotherapy and imaging techniques followed by completion surgery
7. Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer
8. Vaginal morbidity, sexual functioning, and health-related quality of life in cervical cancer survivors: a cross-sectional multicenter study (VAMOS)
9. A preclinical platform for assessing long-term drug efficacy exploiting mechanically tunable scaffolds colonized by a three-dimensional tumor microenvironment
10. Integrating automated liquid handling in the separation workflow of extracellular vesicles enhances specificity and reproducibility
11. Completion surgery after intensity-modulated arc therapy for locally advanced cervical cancer: long-term follow-up and update on surgical outcome and oncologic results of a unique tertiary care single-center retrospective cohort
12. Practice patterns, time trends and quality of care of uterine cancer in Belgium: An analysis of the EFFECT database
13. BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors
14. Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study
15. Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial
16. Zebrafish Avatars: Toward Functional Precision Medicine in Low-Grade Serous Ovarian Cancer
17. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
18. Completeness and selection bias of a Belgian multidisciplinary, registration-based study on the EFFectiveness and quality of Endometrial Cancer Treatment (EFFECT)
19. Safety of pre- or postoperative accelerated radiotherapy in 5 fractions: A randomized pilot trial
20. Effects of hyperthermia on cisplatin tissue penetration and gene expression in peritoneal metastases: results from a randomized trial in ovarian cancer
21. Identification and validation of extracellular vesicle reference genes for the normalization of RT‐qPCR data
22. Performance of MRI for Detection of ≥pT1b Disease in Local Staging of Endometrial Cancer
23. A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial
24. Cancer‐associated fibroblasts mediate resistance to neoadjuvant therapy in breast cancer.
25. Prospective non-interventional BELOVA/BGOG-ov16 study on safety of frontline bevacizumab in elderly patients with FIGO stage IV ovarian cancer: a study of the Belgian and Luxembourg Gynaecological Oncology Group
26. A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial
27. Supplementary Table S2 from Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
28. Supplementary Figure S1 from Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
29. Data from Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
30. Cytokines and Chemokines as Potential Biomarkers for the Outcome of Cervical Cancer Patients
31. Towards the Clinical Implementation of Extracellular Vesicle-Based Biomarker Assays for Cancer
32. Overall Survival and Exploratory Biomarker Analyses of Abemaciclib plus Trastuzumab with or without Fulvestrant versus Trastuzumab plus Chemotherapy in HR+, HER2+ Metastatic Breast Cancer Patients
33. A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial.
34. Identification of potentially actionable genetic variants in epithelial ovarian cancer: a retrospective cohort study.
35. Identification of potentially actionable genetic variants in epithelial ovarian cancer: A retrospective cohort study
36. Reply to Z.R. McCaw et al
37. Gestational choriocarcinoma
38. #1010 PaLACC: a survey on the practice changes of belgian gynecologic oncologists after the LACC trial
39. #243 Patterns and trends in the clinical practice of corpus uteri cancer in Belgium: an analysis of the effect database
40. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study
41. Incidence, evolution and risk factors of hypophosphatemia in patients with solid tumors receiving ferric carboxymaltose: a retrospective cohort study
42. Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pleomorphic Lobular Breast Carcinoma
43. Towards the Clinical Implementation of Extracellular Vesicle-Based Biomarker Assays for Cancer.
44. Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT‐OV26/GOG‐3012 trial
45. Supplementary Table from Distinct Transcriptional Programs in Ascitic and Solid Cancer Cells Induce Different Responses to Chemotherapy in High-Grade Serous Ovarian Cancer
46. Supplementary Figure from Distinct Transcriptional Programs in Ascitic and Solid Cancer Cells Induce Different Responses to Chemotherapy in High-Grade Serous Ovarian Cancer
47. Data from Distinct Transcriptional Programs in Ascitic and Solid Cancer Cells Induce Different Responses to Chemotherapy in High-Grade Serous Ovarian Cancer
48. GRACE-trial: a randomised active-controlled trial for vulvovaginal atrophy in patients with breast cancer on endocrine therapy – study protocol
49. Supplementary Figure 5 from Cancer-Associated Adipose Tissue Promotes Breast Cancer Progression by Paracrine Oncostatin M and Jak/STAT3 Signaling
50. Data from Cancer-Associated Adipose Tissue Promotes Breast Cancer Progression by Paracrine Oncostatin M and Jak/STAT3 Signaling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.